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Life Cycle of Necator americanus Human Hookworm 
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Method† (MOD=Fluorescence) 
7-methoxycoumarin-4-acetyl-GKPILFFRLK(dinitrophenyl)-d-Arg-amide 
(quencher) (fluorophor) 
Cleavage site 
7-methoxycoumarin-4-acetyl-GKPILF    FRLK(dinitrophenyl)-d-Arg-amide 
      (quencher) (fluorophor) 
Na-APR-1wt 
7-methoxycoumarin-4-acetyl-GKPILFFRLK(dinitrophenyl)-d-Arg-amide 
(quencher) (fluorophor) 
Na-APR-1wt 
Anti-Na-APR-1 M74 IgG 
X 
†Reaction Buffer - 50 mM Sodium Acetate (pH = 6.0).  4 
Steps for Generation and Purification of Polyclonal Mouse IgG† 
Protein G Sepharose column 
Nanosep Filter 
Total IgG  
(Spectrophotometer) 
Day  -1 0 42 
S 
B V1 
28 
V2 
B= Bleed 
V= Vaccination (subcutaneously)  
S= Sacrificed 
†50 BALB/c mice vaccinated twice with 9.33µg Na-APR-1 M74 + 74.64µg Alhydrogel®.   
Neutralizing Capacity of purified IgG with 250 ng of Na-APR-1wt and 1µM Cathepsin-D 
Substrate in 50mM Sodium Acetate, pH 6.0.                                             
IgG 
(µg) 
Operators 
% 
Inhibition* 
Intra-plate 
%CV 
Inter Operator  
%CV 
All Runs 
%CV 
Run 1 
5 
1 48.93 4.86 
9.81 
14.57 
2 42.58 6.98 
Run 2 
1 60.44 19.39 
10.22 
2 52.29 7.68 
*RFU of the purified IgG compared to RFU of Negative IgG (commercial mouse IgG). 
Note: All the components were incubated at 37°C for 30 Min. RFU=Relative fluorescence Units.   
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Note: All the components were incubated at 37°C for 30 Min. 
RFU of Positive IgG compared to RFU of Negative IgG (commercial mouse IgG).  
RFU=Relative fluorescence Units.   
Neutralizing Capacity of 8, 4, 2 and 1 µg of IgG with 250ng of Na-APR-1wt 
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Potency Testing of Na-APR-1 M74 Clinical Drug Product†  
BALB/c mice immunized Subcutaneously with Na-APR-1/Alhydrogel® at time 1, 7 months post 
manufacture. (10 mice in 1 group)  
 Na-APR-1  
(µg) 
Alhydrogel® 
(µg) 
Volume  
(ml) 
N/A 400 0.5 
50.00 N/A 0.5 
50.00 400.00 0.5 
28.57 228.56 0.2857 
16.33 130.64 0.1633 
9.33 74.64 0.0933 
5.33 42.64 0.0533 
3.05 24.40 0.0305 
1.74 13.92 0.0174 
0.99 7.92 0.0099 
Day  -1 0 42 
S B= Bleed 
V= Vaccination 
S= Sacrificed 
B 
V1 
28 
B 
V2 
†0.1mg/mL Na-APR-1 (M74) and 0.8mg/mL Alhydrogel® in 150 mM NaCl/10mM imidazole/0.3% Empigen BB  
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Standard Calibration Curves (22 curves from 22 Anti Na-APR-1 M74 IgG ELISA Plates)  
LOQ and RT 
9.33µg Na-APR-1 M74 + 74.64µg Alhydrogel® 
Day  -1 0 42 
S 
B V1 
28 
V2 
B= Bleed 
V= Vaccination (subcutaneously)  
S= Sacrificed 
Standard Reference Serum 
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Fractional Doses           
(μg) 
Responders 
Month 
Na-APR-1 
M74 Alhydrogel® 1 7 
N/A 400 0 0 
50.00 N/A 0 0 
50.00 400.00 9 10 
28.57 228.56 10 6 
16.33 130.64 6 7 
9.33 74.64 3 8 
5.33 42.64 0 1 
3.05 24.40 0 0 
1.74 13.92 0 0 
0.99 7.92 0 0 
ED50 (Effective Dose 50)  
(μg) 14.15 11.46 
95% Fiducial Limits 
 (μg) 10.47 -- 18.93 4.86 -- 27.42 
Responders on Study Day 28 Post-Prime Vaccination 
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ED50 on Study Day 28 Post-Prime Vaccination 
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Relative Potency (RP) of Na-APR-1 M74 Vaccine 
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Summary 
 Five microgram of purified IgG from BALB/c mice vaccinated with 9.33 
µg Na-APR-1 M74 and 76.64 µg Alhydrogel® neutralized 51.06% of 
the enzymatic activity of 250 ng of Na-APR-1wt 
 
 An excellent dose response (% inhibition vs IgG) was observed 
 
 The standard reference serum generated an excellent standard 
calibration curves (SCCs) as well as an excellent global standard 
calibration curve (GSCC) using an Anti-Na-APR-1 M74 IgG ELISA 
 
 Na-APR-1 M74 vaccine generated a potent immune response in Balb/c   
as evident by the generation of ED50 at time 1 and 7 month post-
manufacture 
 
 Na-APR-1 M74 vaccine became 1.23 times more potent at time 7 
month when compared to its potency at time 1 month post-manufacture 
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